Shire Plc Ads (SHPG) 188.21 $SHPG
Shire (SHPG) Gets EU Nod for Label Expansion of Revestive
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 5:36PM CDT
Shire plc (SHPG) announced that the European Commission has granted an extension of the market authorization for its gastrointestinal drug (GI) Revestive for use in the pediatric population.
ABT: 41.89 (+0.53), JNJ: 122.85 (+0.34), SHPG: 188.21 (-1.31), PFE: 36.12 (+0.35)
Shire Receives Extension of Market Authorization in Europe for Revestiveâ-¼ (Teduglutide) for the Treatment of Paediatric Patients with Short Bowel Syndrome (SBS)
PR Newswire - Thu Jul 07, 1:00AM CDT
This press release is intended for a global audience.
SHPG: 188.21 (-1.31)
5 Best Bets for the Q2 Earnings Season
Swarup Gupta - Zacks Investment Research - Tue Jul 05, 11:12AM CDT
Some factors are working in favor of better Q2 results.
GOV: 23.32 (+0.35), RS: 80.18 (+2.00), HNI: 48.15 (+1.08), SHPG: 188.21 (-1.31), AKS: 4.83 (+0.24)
Shire Stock Up Despite Mixed Data on Pipeline Candidate
Zacks Equity Research - Zacks Investment Research - Fri Jul 01, 3:30PM CDT
Shire plc (SHPG) announced disappointing results from a phase II study on pipeline candidate SHP607.
JNJ: 122.85 (+0.34), SHPG: 188.21 (-1.31), PFE: 36.12 (+0.35), BMY: 75.28 (+1.20)
Shire Announces Top-Line Results for Phase 2 Trial of SHP607 in Extremely Premature Infants
PR Newswire - Thu Jun 30, 6:00AM CDT
-- Top-line SHP607 study results in extremely premature infants showed no impact on primary endpoint of reducing the severity of Retinopathy of Prematurity
SHPG: 188.21 (-1.31)
Shire Buys Global Rights to Pfizer's Gastrointestinal Drug
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 4:19PM CDT
Shire plc (SHPG) announced that it will license global rights to all indications of Pfizer's candidate, PF-00547659.
ABT: 41.89 (+0.53), JNJ: 122.85 (+0.34), SHPG: 188.21 (-1.31), PFE: 36.12 (+0.35)
Shire and Kamada Announce FDA Approval of Expanded Label for Self-infusion of GLASSIA for the Treatment of Emphysema Due To Severe AAT Deficiency
PR Newswire - Wed Jun 15, 6:00AM CDT
Shire plc (LSE: SHP, NASDAQ: SHPG) and Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today announced that the United States Food and Drug Administration (FDA) has approved an expanded label for GLASSIA [Alpha-1 Proteinase Inhibitor (Human)], marking the first treatment for adult patients with emphysema due to severe Alpha-1 Antitrypsin (AAT) Deficiency that can be self-infused at home after appropriate training.
SHPG: 188.21 (-1.31), KMDA: 3.70 (+0.07)
Shire Gets Breakthrough Status for Rare Disease Candidates
Zacks Equity Research - Zacks Investment Research - Tue Jun 14, 5:18PM CDT
Shire plc (SHPG) announced that the FDA has granted Breakthrough Therapy Designation to two candidates in its rare diseases pipeline.
ABT: 41.89 (+0.53), SHPG: 188.21 (-1.31), PFE: 36.12 (+0.35), BMY: 75.28 (+1.20)
Shire Announces Completion of Decentralized Procedure in Europe for Immunoglobulin Treatment Cuvitru
PR Newswire Europe - Fri Jun 10, 2:12PM CDT
ZUG, Switzerland, June 10, 2016 /PRNewswire/ --
SHPG: 188.21 (-1.31)
Momenta Pharmaceuticals Announces Data Presentation on M923, a Proposed HUMIRA(R) (adalimumab) Biosimilar, at EULAR 2016
GlobeNewswire - Wed Jun 08, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that key data from a pharmacokinetic/safety study of M923, the Company's lead biosimilar candidate developed in collaboration with Baxalta, now part of Shire plc, will be presented at the European League Against Rheumatism Annual Congress (EULAR) 2016 Annual Meeting in London.
SHPG: 188.21 (-1.31), MNTA: 11.41 (+0.20)
Shire to Participate at Two Upcoming Investor Conferences
PR Newswire Europe - Fri Jun 03, 7:01AM CDT
LEXINGTON, Massachusetts, June 3, 2016 /PRNewswire/ --
SHPG: 188.21 (-1.31)
Shire Completes Combination With Baxalta Creating the Global Leader in Rare Diseases and Highly Specialized Conditions
PR Newswire Europe - Fri Jun 03, 2:41AM CDT
DUBLIN, June 3, 2016 /PRNewswire/ --
SHPG: 188.21 (-1.31), BXLT: 46.02 (-0.18)
5 Top ROE Stocks to Profit in Turbulent Times
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 10:58AM CDT
ROE helps investors distinguish between profit-generating companies from profit burners.
BAK: 11.17 (+0.14), EA: 78.26 (+1.64), SHPG: 188.21 (-1.31), MO: 69.83 (+0.53), LEA: 106.41 (+4.62)
Shire (SHPG) Gets Favorable CHMP Opinion for Revestive
Zacks Equity Research - Zacks Investment Research - Tue May 31, 9:30AM CDT
Shire plc (SHPG) announced that the CHMP has granted a positive opinion for the label expansion of Revestive (teduglutide) 5 mg powder for injection in pediatric patients (aged 1 to 17 years) suffering from short bowel syndrome.
SHPG: 188.21 (-1.31), PFE: 36.12 (+0.35), BXLT: 46.02 (-0.18), BMY: 75.28 (+1.20)
TransDigm Group Set to Join the S&P 500; Helen of Troy and Brocade Communications Systems to Join S&P MidCap 400; Team and MDC Holdings to Join S&P SmallCap 600
PR Newswire - Fri May 27, 4:50PM CDT
S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600 indices:
HELE: 99.27 (-3.42), SPGI: 108.87 (+1.56), TISI: 26.47 (+0.74), BIN.TO: 41.40 (-0.68), MDC: 26.06 (+0.89), SHPG: 188.21 (-1.31), TDG: 269.81 (+7.35), WCN: 73.26 (+0.37), BIN: 31.61 (-1.16), BXLT: 46.02 (-0.18), RKUS: 12.87 (+0.15), BRCD: 9.40 (+0.19)
CORRECTING and REPLACING Baxalta Shareholders Vote to Approve Combination
BusinessWire - Fri May 27, 9:00AM CDT
First paragraph, second sentence of release should read: Baxalta shareholders approved the definitive merger agreement with Shire, dated as of January 11, 2016, and the merger transaction, with approximately 76.9 percent of shares outstanding cast in favor of the proposal, which represents approximately 98.9 percent of the votes cast at the meeting (instead of Baxalta shareholders approved the definitive merger agreement with Shire, dated as of January 11, 2016, and the merger transaction, with approximately 98.9 percent of shares outstanding cast in favor of the proposal).
SHPG: 188.21 (-1.31), BXLT: 46.02 (-0.18)
Baxalta Shareholders Vote to Approve Combination
BusinessWire - Fri May 27, 8:00AM CDT
Baxalta Incorporated (NYSE:BXLT) today announced the results of a vote on the proposals identified in the definitive proxy statement/prospectus, dated April 18, 2016, at a special meeting of shareholders held earlier this morning relating to the proposed combination with Shire plc (LSE: SHP, NASDAQ: SHPG). Baxalta shareholders approved the definitive merger agreement with Shire, dated as of January 11, 2016, and the merger transaction, with approximately 98.9 percent of shares outstanding cast in favor of the proposal.
SHPG: 188.21 (-1.31), BXLT: 46.02 (-0.18)
Shire (SHPG) Gets EU Nod for Label Expansion of Revestive
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 5:36PM CDT
Shire plc (SHPG) announced that the European Commission has granted an extension of the market authorization for its gastrointestinal drug (GI) Revestive for use in the pediatric population.
ABT: 41.89 (+0.53), JNJ: 122.85 (+0.34), SHPG: 188.21 (-1.31), PFE: 36.12 (+0.35)
Shire Receives Extension of Market Authorization in Europe for Revestiveâ-¼ (Teduglutide) for the Treatment of Paediatric Patients with Short Bowel Syndrome (SBS)
PR Newswire - Thu Jul 07, 1:00AM CDT
This press release is intended for a global audience.
SHPG: 188.21 (-1.31)
5 Best Bets for the Q2 Earnings Season
Swarup Gupta - Zacks Investment Research - Tue Jul 05, 11:12AM CDT
Some factors are working in favor of better Q2 results.
GOV: 23.32 (+0.35), RS: 80.18 (+2.00), HNI: 48.15 (+1.08), SHPG: 188.21 (-1.31), AKS: 4.83 (+0.24)
Shire Stock Up Despite Mixed Data on Pipeline Candidate
Zacks Equity Research - Zacks Investment Research - Fri Jul 01, 3:30PM CDT
Shire plc (SHPG) announced disappointing results from a phase II study on pipeline candidate SHP607.
JNJ: 122.85 (+0.34), SHPG: 188.21 (-1.31), PFE: 36.12 (+0.35), BMY: 75.28 (+1.20)
Shire Announces Top-Line Results for Phase 2 Trial of SHP607 in Extremely Premature Infants
PR Newswire - Thu Jun 30, 6:00AM CDT
-- Top-line SHP607 study results in extremely premature infants showed no impact on primary endpoint of reducing the severity of Retinopathy of Prematurity
SHPG: 188.21 (-1.31)
Shire Buys Global Rights to Pfizer's Gastrointestinal Drug
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 4:19PM CDT
Shire plc (SHPG) announced that it will license global rights to all indications of Pfizer's candidate, PF-00547659.
ABT: 41.89 (+0.53), JNJ: 122.85 (+0.34), SHPG: 188.21 (-1.31), PFE: 36.12 (+0.35)
Shire and Kamada Announce FDA Approval of Expanded Label for Self-infusion of GLASSIA for the Treatment of Emphysema Due To Severe AAT Deficiency
PR Newswire - Wed Jun 15, 6:00AM CDT
Shire plc (LSE: SHP, NASDAQ: SHPG) and Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today announced that the United States Food and Drug Administration (FDA) has approved an expanded label for GLASSIA [Alpha-1 Proteinase Inhibitor (Human)], marking the first treatment for adult patients with emphysema due to severe Alpha-1 Antitrypsin (AAT) Deficiency that can be self-infused at home after appropriate training.
SHPG: 188.21 (-1.31), KMDA: 3.70 (+0.07)
Shire Gets Breakthrough Status for Rare Disease Candidates
Zacks Equity Research - Zacks Investment Research - Tue Jun 14, 5:18PM CDT
Shire plc (SHPG) announced that the FDA has granted Breakthrough Therapy Designation to two candidates in its rare diseases pipeline.
ABT: 41.89 (+0.53), SHPG: 188.21 (-1.31), PFE: 36.12 (+0.35), BMY: 75.28 (+1.20)
Shire Announces Completion of Decentralized Procedure in Europe for Immunoglobulin Treatment Cuvitru
PR Newswire Europe - Fri Jun 10, 2:12PM CDT
ZUG, Switzerland, June 10, 2016 /PRNewswire/ --
SHPG: 188.21 (-1.31)
Momenta Pharmaceuticals Announces Data Presentation on M923, a Proposed HUMIRA(R) (adalimumab) Biosimilar, at EULAR 2016
GlobeNewswire - Wed Jun 08, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that key data from a pharmacokinetic/safety study of M923, the Company's lead biosimilar candidate developed in collaboration with Baxalta, now part of Shire plc, will be presented at the European League Against Rheumatism Annual Congress (EULAR) 2016 Annual Meeting in London.
SHPG: 188.21 (-1.31), MNTA: 11.41 (+0.20)
Shire to Participate at Two Upcoming Investor Conferences
PR Newswire Europe - Fri Jun 03, 7:01AM CDT
LEXINGTON, Massachusetts, June 3, 2016 /PRNewswire/ --
SHPG: 188.21 (-1.31)
Shire Completes Combination With Baxalta Creating the Global Leader in Rare Diseases and Highly Specialized Conditions
PR Newswire Europe - Fri Jun 03, 2:41AM CDT
DUBLIN, June 3, 2016 /PRNewswire/ --
SHPG: 188.21 (-1.31), BXLT: 46.02 (-0.18)
5 Top ROE Stocks to Profit in Turbulent Times
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 10:58AM CDT
ROE helps investors distinguish between profit-generating companies from profit burners.
BAK: 11.17 (+0.14), EA: 78.26 (+1.64), SHPG: 188.21 (-1.31), MO: 69.83 (+0.53), LEA: 106.41 (+4.62)
Shire (SHPG) Gets Favorable CHMP Opinion for Revestive
Zacks Equity Research - Zacks Investment Research - Tue May 31, 9:30AM CDT
Shire plc (SHPG) announced that the CHMP has granted a positive opinion for the label expansion of Revestive (teduglutide) 5 mg powder for injection in pediatric patients (aged 1 to 17 years) suffering from short bowel syndrome.
SHPG: 188.21 (-1.31), PFE: 36.12 (+0.35), BXLT: 46.02 (-0.18), BMY: 75.28 (+1.20)
TransDigm Group Set to Join the S&P 500; Helen of Troy and Brocade Communications Systems to Join S&P MidCap 400; Team and MDC Holdings to Join S&P SmallCap 600
PR Newswire - Fri May 27, 4:50PM CDT
S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600 indices:
HELE: 99.27 (-3.42), SPGI: 108.87 (+1.56), TISI: 26.47 (+0.74), BIN.TO: 41.40 (-0.68), MDC: 26.06 (+0.89), SHPG: 188.21 (-1.31), TDG: 269.81 (+7.35), WCN: 73.26 (+0.37), BIN: 31.61 (-1.16), BXLT: 46.02 (-0.18), RKUS: 12.87 (+0.15), BRCD: 9.40 (+0.19)
CORRECTING and REPLACING Baxalta Shareholders Vote to Approve Combination
BusinessWire - Fri May 27, 9:00AM CDT
First paragraph, second sentence of release should read: Baxalta shareholders approved the definitive merger agreement with Shire, dated as of January 11, 2016, and the merger transaction, with approximately 76.9 percent of shares outstanding cast in favor of the proposal, which represents approximately 98.9 percent of the votes cast at the meeting (instead of Baxalta shareholders approved the definitive merger agreement with Shire, dated as of January 11, 2016, and the merger transaction, with approximately 98.9 percent of shares outstanding cast in favor of the proposal).
SHPG: 188.21 (-1.31), BXLT: 46.02 (-0.18)
Baxalta Shareholders Vote to Approve Combination
BusinessWire - Fri May 27, 8:00AM CDT
Baxalta Incorporated (NYSE:BXLT) today announced the results of a vote on the proposals identified in the definitive proxy statement/prospectus, dated April 18, 2016, at a special meeting of shareholders held earlier this morning relating to the proposed combination with Shire plc (LSE: SHP, NASDAQ: SHPG). Baxalta shareholders approved the definitive merger agreement with Shire, dated as of January 11, 2016, and the merger transaction, with approximately 98.9 percent of shares outstanding cast in favor of the proposal.
SHPG: 188.21 (-1.31), BXLT: 46.02 (-0.18)
